ALCAM and inflammatory bowel disease: Increased expression of both CD6 and CD166/ALCAM has been reported in inflamed mucosa from IBD patients, a fact that is attributed to higher CD6-expressing T cell infiltration rather than surface CD6 expression levels (54).